NICE technology appraisal guidance
Issued: April 2012
TA254

Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta254

1 Guidance

1.1 Fingolimod is recommended as an option for the treatment of highly active relapsing–remitting multiple sclerosis in adults, only if:

  • they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with beta interferon, and

  • the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme.

1.2 People currently receiving fingolimod whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.